StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a report published on Wednesday. The firm issued a hold rating on the biotechnology company’s stock.
Separately, Maxim Group upgraded shares of Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 price target for the company in a research note on Thursday, July 11th.
Check Out Our Latest Research Report on BCLI
Brainstorm Cell Therapeutics Trading Down 4.2 %
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). During the same quarter last year, the firm posted ($0.27) EPS. Research analysts predict that Brainstorm Cell Therapeutics will post -0.19 EPS for the current fiscal year.
Institutional Trading of Brainstorm Cell Therapeutics
An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC acquired a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics at the end of the most recent quarter. 14.33% of the stock is currently owned by institutional investors.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
Featured Articles
- Five stocks we like better than Brainstorm Cell Therapeutics
- What Are the FAANG Stocks and Are They Good Investments?
- 3 Momentum Trades for October With Ample Upside Ahead
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- Overbought Stocks Explained: Should You Trade Them?
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.